{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:46:25Z","timestamp":1791315985611,"version":"4.3.1"},"reference-count":107,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2006,6,20]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To update the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Update Methodology<\/jats:title><jats:p>The Update Committee completed a review and analysis of data published from 1998 thru February 2006. The literature review focused on published randomized controlled trials, and systematic reviews and meta-analyses of published phase II and phase III randomized controlled trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recommendations<\/jats:title><jats:p>The three-drug combination of a 5-hydroxytryptamine-3 (5-HT<jats:sub>3<\/jats:sub>) serotonin receptor antagonist, dexamethasone, and aprepitant is recommended before chemotherapy of high emetic risk. For persons receiving chemotherapy of high emetic risk, there is no group of patients for whom agents of lower therapeutic index are appropriate first-choice antiemetics. These agents should be reserved for patients intolerant of or refractory to 5-HT<jats:sub>3<\/jats:sub>serotonin receptor antagonists, neurokinin-1 receptor antagonists, and dexamethasone. The three-drug combination of a 5-HT<jats:sub>3<\/jats:sub>receptor serotonin antagonist, dexamethasone, and aprepitant is recommended for patients receiving an anthracycline and cyclophosphamide. For patients receiving other chemotherapy of moderate emetic risk, the Update Committee continues to recommend the two-drug combination of a 5-HT<jats:sub>3<\/jats:sub>receptor serotonin antagonist and dexamethasone. In all patients receiving cisplatin and all other agents of high emetic risk, the two-drug combination of dexamethasone and aprepitant is recommended for the prevention of delayed emesis. The Update Committee no longer recommends the combination of a 5-HT<jats:sub>3<\/jats:sub>serotonin receptor antagonist and dexamethasone for the prevention of delayed emesis after chemotherapeutic agents of high emetic risk.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The Update Committee recommends that clinicians administer antiemetics while considering patients' emetic risk categories and other characteristics.<\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2006.06.9591","type":"journal-article","created":{"date-parts":[[2006,5,23]],"date-time":"2006-05-23T00:45:24Z","timestamp":1148345124000},"page":"2932-2947","source":"Crossref","is-referenced-by-count":596,"title":["American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006"],"prefix":"10.1200","volume":"24","author":[{"given":"Mark G.","family":"Kris","sequence":"first","affiliation":[{"name":"From the American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Hesketh","sequence":"additional","affiliation":[{"name":"From the American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Somerfield","sequence":"additional","affiliation":[{"name":"From the American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Feyer","sequence":"additional","affiliation":[{"name":"From the American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Clark-Snow","sequence":"additional","affiliation":[{"name":"From the American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Koeller","sequence":"additional","affiliation":[{"name":"From the American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary R.","family":"Morrow","sequence":"additional","affiliation":[{"name":"From the American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence W.","family":"Chinnery","sequence":"additional","affiliation":[{"name":"From the American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice J.","family":"Chesney","sequence":"additional","affiliation":[{"name":"From the American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Gralla","sequence":"additional","affiliation":[{"name":"From the American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Grunberg","sequence":"additional","affiliation":[{"name":"From the American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2971"},{"key":"R2","unstructured":"Smith TJ, Somerfield MR: The ASCO experience with evidence-based clinical practice guidelines. Oncology (Williston Park) 11:223,1997-227,"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464070-00013"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.19.3409"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20001201)89:11<2301::AID-CNCR19>3.0.CO;2-6"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-004-0672-8"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj944"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-004-0756-5"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-004-0718-y"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-004-0699-x"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21343"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-004-0703-5"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-004-0704-4"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.730"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-004-0705-3"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-004-0702-6"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj944"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1007\/BF00874423"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(91)90048-I"},{"key":"R23","unstructured":"Fetting JH, Grochow LB, Folstein MF, et al: The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat Rep 66:1487,1982-1493,"},{"key":"R24","unstructured":"Clark R, Tyson L, Frisone M: A correlation of objective (OBJ) and subjective (SUBJ) parameters in assessing antiemetic regimens (AER). Oncol Nurs Forum 12:96,1985, (suppl)"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.8.1142"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.103"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008471812316"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg417"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11817"},{"key":"R30","unstructured":"Aapro M, Bertoli L, Lordick F, et al: Palonosetron is effective in preventing acute and delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supp Care Cancer 11:391,2003, (abstr A17)"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.9.2937"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.09.040"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.095"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11433"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.01.024"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00066-3"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901213400304"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11320"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.050"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-004-0946-3"},{"key":"R41","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-005-1005-4"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198110153051601"},{"key":"R43","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(96)00276-6"},{"key":"R44","unstructured":"Hainsworth JD: The use of ondansetron in patients receiving multiple-day cisplatin regimens. Semin Oncol 19:48,1992-52,"},{"key":"R45","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199404000-00010"},{"key":"R46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.10.1379"},{"key":"R47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.1.108"},{"key":"R48","doi-asserted-by":"crossref","unstructured":"Koo WH, Ang PT: Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. Ann Oncol 7:71,1996-74,","DOI":"10.1093\/oxfordjournals.annonc.a010483"},{"key":"R49","doi-asserted-by":"publisher","DOI":"10.1159\/000227645"},{"key":"R50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.5.1050"},{"key":"R51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199003223221204"},{"key":"R52","unstructured":"Kris MG, Radford J, Pizzo B, et al: Dose ranging antiemetic trial of the NK-1 receptor antagonist CP-122,721: A new approach for acute and delayed emesis following cisplatin. Proc Am Soc Clin Oncol 547: 1996 (abstr 1780)"},{"key":"R53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199501053320101"},{"key":"R54","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199106000-00010"},{"key":"R55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.8.2966"},{"key":"R56","unstructured":"Navari R, Madajewicz S, Anderson N, et al: Oral ondansetron effectively controls cisplatin-induced delayed emesis. Proc Am Soc Clin Oncol 14:523,1995, (abstr 1720)"},{"key":"R57","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.11.817"},{"key":"R58","doi-asserted-by":"crossref","unstructured":"Navari RM, Reinhardt RR, Gralla RJ, et al: Prevention of cisplatin-induced emesis by a neurokinin-1-receptor antagonist. N Engl J Med 340:1927,1999-1928,","DOI":"10.1056\/NEJM199906173402417"},{"key":"R59","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19951115)76:10<1821::AID-CNCR2820761022>3.0.CO;2-Y"},{"key":"R60","unstructured":"Strum S, McDermed J, Abrahano-Umall R, et al: Management of cisplatin (DDP)-induced delayed-onset nausea (N) and vomiting (V): Preliminary results with 2 drug regimens. Proc Am Soc Clin Oncol 4:263,1985,"},{"key":"R61","doi-asserted-by":"crossref","unstructured":"Johnston D, Latreille J, Laberge F, et al: Preventing nausea and vomiting during days 2-7 following high dose cisplatin chemotherapy (HDCP): A study by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). Proc Am Soc Clin Oncol 14:529,1995,","DOI":"10.1016\/0959-8049(95)96450-R"},{"key":"R62","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.53.4.447"},{"key":"R63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199003223221205"},{"key":"R64","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-113-11-834"},{"key":"R65","doi-asserted-by":"publisher","DOI":"10.1007\/BF00686171"},{"key":"R66","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/2.suppl_2.107"},{"key":"R67","unstructured":"Gandara DR, Harvey WH, Monaghan GG, et al: The delayed-emesis syndrome from cisplatin: Phase III evaluation of ondansetron versus placebo. Semin Oncol 19:67,1992-71,"},{"key":"R68","doi-asserted-by":"publisher","DOI":"10.1007\/BF00365581"},{"key":"R69","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008247830641"},{"key":"R70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304153281503"},{"key":"R71","doi-asserted-by":"crossref","unstructured":"Aapro M, Selak M, Lichinitser D, et al: Palonosetron (PALO) is more effective than ondansetron (OND) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC): Results of a phase III trial. Proc Am Soc Clin Oncol 22:726,2003, (abstr 2918)","DOI":"10.1200\/jco.2004.22.90140.8049"},{"key":"R72","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.3.1174"},{"key":"R73","doi-asserted-by":"crossref","unstructured":"Roila F: Prevention of cisplatin-induced delayed emesis: Still unsatisfactory. Support Care Cancer 8:229,1999-232,","DOI":"10.1007\/s005200050290"},{"key":"R74","doi-asserted-by":"crossref","unstructured":"Gridelli C, Ianniello GP, Ambrosini G, et al: A multicentre, double-blind, randomized trial comparing ondansetron versus ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced delayed emesis. Int J Oncol 10:395,1997-400,","DOI":"10.3892\/ijo.10.2.395"},{"key":"R75","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005253422102"},{"key":"R76","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19881215)62:12<2607::AID-CNCR2820621226>3.0.CO;2-S"},{"key":"R77","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.54.5.593"},{"key":"R78","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198212093072402"},{"key":"R79","unstructured":"Morrow GR: Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients. J Natl Cancer Inst 68:585,1982-588,"},{"key":"R80","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1984.2.10.1170"},{"key":"R81","doi-asserted-by":"publisher","DOI":"10.3109\/07357908809080655"},{"key":"R82","doi-asserted-by":"publisher","DOI":"10.1016\/0885-3924(91)90011-R"},{"key":"R83","doi-asserted-by":"publisher","DOI":"10.1159\/000227633"},{"key":"R84","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.185"},{"key":"R85","doi-asserted-by":"publisher","DOI":"10.1159\/000226675"},{"key":"R86","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.39.2.89"},{"key":"R87","doi-asserted-by":"crossref","unstructured":"Fallowfield LJ: Behavioural interventions and psychological aspects of care during chemotherapy. Eur J Cancer 28A:S39,1992-S41, (suppl 1)","DOI":"10.1016\/0959-8049(92)90636-G"},{"key":"R88","doi-asserted-by":"publisher","DOI":"10.1080\/08880010050120791"},{"key":"R89","doi-asserted-by":"publisher","DOI":"10.1097\/00002820-200308000-00012"},{"key":"R90","doi-asserted-by":"publisher","DOI":"10.1080\/08880010490427351"},{"key":"R91","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199908)33:2<99::AID-MPO7>3.0.CO;2-P"},{"key":"R92","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199907000-00007"},{"key":"R93","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.24.432"},{"key":"R94","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200018060-00002"},{"key":"R95","doi-asserted-by":"crossref","unstructured":"Tsuchida Y, Hayashi Y, Asami K, et al: Effects of granisetron in children undergoing high-dose chemotherapy: A multi-institutional, cross-over study. Int J Oncol 14:673,1999-679,","DOI":"10.3892\/ijo.14.4.673"},{"key":"R96","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.8.1136"},{"key":"R97","doi-asserted-by":"crossref","unstructured":"Kris MG, Tyson LB, Gralla RJ, et al: Extrapyramidal reactions with high-dose metoclopramide. N Engl J Med 309:433,1983-434,","DOI":"10.1056\/NEJM198308183090718"},{"key":"R98","unstructured":"Hunter AE, Prentice HG, Pothecary K, et al: Granisetron, a selective 5-HT3 receptor antagonist, for the prevention of radiation induced emesis during total body irradiation. Bone Marrow Transplant 7:439,1991-441,"},{"key":"R99","unstructured":"Prentice HG, Cunningham S, Gandhi L, et al: Granisetron in the prevention of irradiation-induced emesis. Bone Marrow Transplant 15:445,1995-448,"},{"key":"R100","doi-asserted-by":"publisher","DOI":"10.3109\/10428199209049784"},{"key":"R101","unstructured":"Scarantino CW, Ornitz RD, Hoffman LG, et al: Radiation-induced emesis: Effects of ondansetron. Semin Oncol 19:38,1992-43,"},{"key":"R102","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)90356-5"},{"key":"R103","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9260(79)80203-2"},{"key":"R104","doi-asserted-by":"publisher","DOI":"10.3109\/08880019609030823"},{"key":"R105","doi-asserted-by":"crossref","unstructured":"Miralbell R, Coucke P, Behrouz F, et al: Nausea and vomiting in fractionated radiotherapy: A prospective on-demand trial of tropisetron rescue for non-responders to metoclopramide. Eur J Cancer 31A:1461,1995-1464,","DOI":"10.1016\/0959-8049(95)00208-Z"},{"key":"R106","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9260(87)80062-4"},{"key":"R107","unstructured":"Schwella N, Konig V, Schwerdtfeger R, et al: Ondansetron for efficient emesis control during total body irradiation. Bone Marrow Transplant 13:169,1994-171,"},{"key":"R108","doi-asserted-by":"publisher","DOI":"10.1016\/S0936-6555(05)80086-X"},{"key":"R109","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010675"},{"key":"R110","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9260(87)80151-4"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2006.06.9591","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T13:37:11Z","timestamp":1683466631000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2006.06.9591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,20]]},"references-count":107,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2006,6,20]]}},"alternative-id":["10.1200\/JCO.2006.06.9591"],"URL":"https:\/\/doi.org\/10.1200\/jco.2006.06.9591","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,20]]}}}